



May 2026



**\$7,000,000**

Underwritten Registered  
Direct Offering



*For more information please  
contact:*

### Investment Banking

Sean Hagerty, PhD  
Managing Director  
Direct: +1 (212) 970-5168  
shagerty@dboralcapital.com

John Park  
Director  
Direct: +1 (929) 528-0864  
jpark@dboralcapital.com

Alex Piechucki  
Analyst  
Direct: +1 (929) 528-0907  
apiechucki@dboralcapital.com

Michael Fellman  
Analyst  
Direct: +1 (929) 528-0986  
mfellman@dboralcapital.com

### Equity Capital Markets

Philip Wiederlight  
Chief Operating Officer  
Direct: +1 (929) 625-1539  
pwiederlight@dboralcapital.com

Mark Iorio  
Head of Equity Capital Markets  
Direct: +1 (929) 528-0913  
miorio@dboralcapital.com

## **D. Boral Capital Acted as Financial Advisor to Clene Inc. (Nasdaq: CLNN) in Connection with its \$7,000,000 Underwritten Registered Direct Offering**

### Transaction Information

On May 5, 2026, Clene Inc. (Nasdaq: CLNN) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), announced the pricing of an Underwritten Registered Direct Offering of 1,000,000 shares of common stock at a purchase price of \$7.00 per share to a single investor. The gross proceeds from the Offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be \$7,000,000.

D. Boral Capital LLC acted as Financial Advisor for the Offering.

### About Clene

Clene Inc., along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8<sup>®</sup> is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8<sup>®</sup> is a federally registered trademark of Clene Nanomedicine, Inc. The Company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.

### About D. Boral Capital

D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America.

A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately \$35 billion in capital since its inception in 2020, executing ~400 transactions across a broad range of investment banking products.

D. Boral Capital is a member of FINRA and SIPC.

